Synergistic Effects of Taurine and Temozolomide Via Cell Proliferation Inhibition and Apoptotic Induction on U-251 MG Human Glioblastoma Cells

Thanakorn Surarak1*, Pathanin Chantree2,3, Kant Sangpairoj2,3

Abstract

Objective: The combination treatment is a way to improve the therapeutic strategy of temozolomide (TMZ) -resistant glioblastoma (GBM). Taurine (TAU) has the potential to inhibit growth in various cancer cells. The aim of this study was to examine the combined effects of TMZ and TAU on cultured human GBM, U-251 MG cells. Methods: The cells were incubated with TMZ, TAU, and the combination of both in various ratios. MTT assay was performed to measure the cell viability of the treatments and then the synergistic interactions were evaluated by the Chou-Talalay method. The cell cycle and apoptotic properties of the combined treatment on U-251 MG cells were examined by flow cytometry. The Hoechst 33342 stainings were applied to visualize the morphologic change in the apoptotic process. Results: The combined treatment with a dose reduction of each expressed synergistic effect on the decrease of cell viability. The study on the cell cycle resulted in G2/M phase arrest with increasing apoptotic cells in the SubG1 phase. Moreover, the apoptotic effects of the combinations on U-251 MG cells were explained by the increase of apoptotic cells in both early and late stages and illustrated by some characteristics of the apoptotic process including condensed chromatin and fragmented nuclei. Conclusion: The study showed that the combination between TMZ and TAU has a potential in anticancer properties against U-251 MG manifested by the induction of G2/M arrest and apoptosis. These results suggest that this combination may be useful to enhance the efficacy and reduce some adverse events of GBM treatment in the future.

Keywords: Temozolomide- taurine- U-251 MG cells- synergism- glioblastoma
patients also have a chance to experience recurrence of the disease (Lee et al., 2016). The common adverse effects of TMZ are myelosuppression, especially neutropenia and thrombocytopenia (Zhang et al., 2012).

Taurine (TAU) is a sulfur-containing amino acid that can be synthesized from methionine or cysteine mainly in the liver. TAU has been found mostly in neurons in the central nervous system and skeletal muscle cells (Seidel et al., 2018). Other sources of TAU have also been found in natural food such as meat, fish, and seafood as well as in energy drinks as a popular ingredient (Curran et al., 2017). It plays a role in the physiological processes in the body such as the development of the fetus, lung function, mitochondrial function, anti-oxidative defense, Ca²⁺-homeostasis (Goron et al., 2018; Schaffer et al., 2018). Previously, TAU has also exerted some pharmacological studies have been found that it has the potential to inhibit the proliferation and induce apoptosis in several types of cancer cells including human colon cancer cells (Zhang et al., 2014), human nasopharyngeal carcinoma cells (He et al., 2018), colorectal cancer cells (Liu et al., 2018), breast cancer cells (Zhang et al., 2015), human lung cancer cells (Tu et al., 2018) and glioblastoma cells (Gao et al., 2016) both in In vitro and xenograft model.

Following the principle of chemotherapy, a physician usually prescribes a combination of the medications to treat the varieties of cancer. Previous studies have reported that the combination of TMZ and resveratrol enhanced cytotoxicity of TMZ in U87 MG (Lin et al., 2012) and using of TMZ together with chloroquine reduced the growth of GBM by G/M arrest (Lee, et al., 2015) as well as the combined TMZ with caffeine increased cytotoxicity and reduced colony formation of GMB (Li et al., 2018). Moreover, the study in the combination of TAU and cyclophosphamide has been reported that it reduced Ehrlich ascites carcinoma proliferation in vivo (Ibrahima et al., 2018). Additionally, the combined medications provide some benefits such as enhancing the efficacy of treatment and reduction of adverse effects of the medications.

Interestingly, TMZ combined with TAU has no study in glioblastoma. This study aims to investigate the antitumor effect of the combination between TMZ and TAU on glioblastoma. The results might pave the way to develop a new treatment strategy for glioblastoma in the future.

**Materials and Methods**

**Chemical and cell culture**

Temozolomide (TMZ) and taurine (TAU) were obtained from Sigma–Aldrich, St. Louis, MO. (Product Number: T2577 and T4571). The 100 mM of TMZ stock solution and 400 mM of TAU stock solution were prepared by dissolving in dimethyl sulfoxide (DMSO) and distilled water, respectively and then they were stored at -20°C until use. U-251 MG cell line was purchased from Cell Line Services, Germany. Cells were cultured in DMEM medium supplemented with 1% penicillin-streptomycin (10,000 U/mL) and 10% heat-inactivated fetal bovine serum (Gibco BRL, Gaithersburg, Md., U.S.A.) and maintained at 37°C in an incubator containing 5% CO₂ and 95% humidity.

**Cytotoxicity analysis and synergistic interaction evaluation**

To determine the half-maximal inhibitory concentration (IC₅₀) of TMZ and TAU, U251-MG cells were seeded into a 96-well plate overnight and then treated with diluted TMZ or TAU in various concentrations for 24 h and 48 h. Afterward, the MTT working solution (Sigma-Aldrich, USA) was added to each well at a final concentration of 30 μg/mL and further incubated for 3 h. OD values were measured by using a spectrophotometer with wavelengths at 562 and 630 nm and the results were used to calculate IC₅₀ value. Thereafter, U-251 MG cells were treated with nine concentrations of combined doses between TMZ and TAU including 130%, 100% and 70% of IC₅₀ of TAU, and 100%, 75%, and 50% of maximal concentration of dissolved TMZ in a 3x3 matrix table for 24 h and 48 h. The treated cells were analyzed by MTT assay. The synergistic effects were further evaluated by CompuSyn software (ComboSyn, Inc.) based on the theorem of Chou-Talalay in a previous study (Chou, 2010).

**Analysis of apoptotic cells by flow cytometry**

Cells were treated with a combination between TMZ and TAU or a single substance for 24 h and 48 h. After that, treated cells were analyzed for the distribution of apoptotic stages by using Alexa Fluor™ 488 Antibody Labeling Kit (Invitrogen™). Briefly, 1 × 10⁵ harvested cells were incubated with Alexa Fluor™ 488 Annexin V and Propidium iodide (PI) in the binding buffer and incubated for 15 min at room temperature in the dark. The distribution of apoptotic stages was evaluated by the FACSCalibur flow cytometer (Becton Dickinson, USA).

**Analysis of apoptosis by determining nuclear condensation**

The nuclear condensation and fragmentation were determined by Hoechst 33342 staining (Sigma-Aldrich, USA). After treatment with a combination between TMZ and TAU or a single substance, the culture media were discarded, and cells were washed in PBS. Afterward, treated cells were incubated with 10 mg/mL Hoechst stock solution diluted at 1:5:1,000 in PBS for 10 minutes in a dark condition at room temperature. Lastly, cells were washed 3 times in PBS and visualized by a fluorescence microscope at 480 nm.

**Flow cytometry analysis of DNA content**

Treated cells were evaluated cell cycle distribution by using PI staining. Briefly, after incubated with various concentrations of the combination doses between TMZ and TAU for 24 h and 48 h, 2 × 10⁵ treated cells were fixed with 81% ethanol and overnight incubated in a -20°C. Cells were washed twice in PBS to remove the ethanol. Cells were then re-suspended in FxCycle™ PI/RNase Staining Solution (InvitrogenTM) and incubated in the dark at room temperature for 15 min. The DNA content was analyzed using the FACSCalibur flow cytometer (Becton Dickinson, USA).
**Table 1.** The Combination Codes Indicate Concentrations of TAU and TMZ and CI at 24 h and 48 h

| Combination codes | TAU (mM) | TMZ (µM) | 24 h | 48 h |
|-------------------|----------|----------|------|------|
| A1                | 24       | 500      | 0.545| 0.93120|
| A2                | 24       | 375      | 0.564| 0.87512|
| A3                | 24       | 250      | 0.554| 0.89105|
| B1                | 18       | 500      | 0.498| 0.80599|
| B2                | 18       | 375      | 0.495| 0.80152|
| B3                | 18       | 250      | 0.468| 0.85082|
| C1                | 12       | 500      | 0.350| 0.85169|
| C2                | 12       | 375      | 0.363| 0.79739|
| C3                | 12       | 250      | 0.347| 0.81543|

**Statistical analysis**

Data were expressed as the mean ± SEM obtained from triplicate experiments. Statistical analysis was performed using one-way analysis of variance (ANOVA) with Turkey post hoc test provided in GraphPad Prism 6 software. The values obtained in the assays were statistically significant when P < 0.05.

**Results**

**Cytotoxicity effect of Taurine, temozolomide and the combinations on U-251 MG cells**

After treatment for 24 h and 48 h with various concentrations of TAU or TMZ on U-251 MG cells, the MTT assay was performed to investigate the cytotoxicity of each of the substances. The percentages of cell viability of U-251 MG cells of the TAU treatment were decreased in a concentration-dependent manner from 5 to 50 mM compared with the control group (Figure 1a). The 50% inhibitory concentrations (IC₅₀) of TAU for U-251 MG cells were 20.23 ± 1.99 mM and 19.72 ± 2.33 mM at 24 h and 48 h, respectively. At 500 µM of temozolomide, %cell viability at 24 h and 48 h were 93.92 ± 3.43 and 97.83 ± 7.83, respectively (Figure 1b). The combinations were determined as the combination codes (Table 1). The cell viability of the combinations was investigated by MTT assay. The percentages of the cell viability of the combination A1, A2, A3, B1, B2, B3 were significantly decreased when compared with control and were comparable with TAU24 at 24 h and 48 h. Similarly, at only 48h %cell viability of the combinations C1 and C2 was comparable with TAU24 (Figure 1c).

The percentage of cell death of the combinations was analyzed using CompuSyn software based on Chou-Talalay method to evaluate the interactions indicated by the combination indices (CI) where CI < 1, = 1, and > 1 represent synergistic, additive, and antagonistic interaction, respectively. As result shown in Figure 1D, all the combinations obtained CI <1. Moreover, the more CI value was decreased, the stronger synergistic interaction was indicated. Thus, C2 obtained the most synergistic interaction among other combinations.**
Figure 1. Percent of Cell Viability of U-251 MG after Treatment with Various Concentrations of TAU (a) or TMZ (b) or the combinations (c) for 24 and 48 h, after that, the IC\textsubscript{50} value of TAU or TMZ was calculated. The histogram is presented in mean ± SEM. $ p < 0.05$, $$ p < 0.01$ compared with the group treated only by TAU 24 mM (TAU24) at same time.

Figure 2. The Apoptotic Effects of the Combinations in U-251 MG Cells were Observed by Using Flow Cytometry. (a-j) represent the results of cells incubated with 0, TMZ 500 µM, TAU 24 mM, B2, and C2 for 24 h (a-e) and 48 h (f-j), respectively. The numbers of AnnexinV-FITC and PI-positive cells are shown in the scattered plot. The percentage of cell populations in early (k) and late (l) apoptotic stages per total cells at 24 h and 48 h are shown in the histograms. *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$ compared with control at same time. #$p < 0.05$ compared with TMZ500 at same time. $p < 0.05$ compared with TAU24 at same time.
Synergistic Effects of Taurine and Temozolomide on Glioblastoma Cell

Figure 3. Detection of Condensed Chromosomes and Fragmented Nuclei in Treated U-251 MG Cells. (a-h) represents the results of cells stained with Hoechst 33342 and further visualized under a fluorescence microscope after incubated with 0, TAU 24 mM, TMZ 500 µM, and C2 for 24 h (a-d) and 48 h (e-h), respectively. Arrowheads display chromatin condensation and nuclear fragmentation. Scale bar = 50 µm.

Effect of the combinations on cell cycle distribution of U-251 MG cells

After U-251 MG cells were treated with the experimental substances, the cells were stained with PI and the distribution of each phase in the cell cycle was investigated using flow cytometry. The results revealed that the cells treated with TMZ, B2, and C2 could be induced a G2/M arrest only for 24h treatment (Figure 4b, d, e, n). On the other hand, the percentage of cell distribution was significantly increased in the SubG1 phase when compared to a control group after 48 h treatment with TMZ, B2, and C2 (Figure 4k).

Expression analyses of apoptotic related proteins by western blot

Apoptotic effects at the protein expression level of the...
Figure 4. Cell Cycle Analyses of U-251 MG Cells Treated with a Single Agent, or the Combinations were Observed by Using Flow Cytometry. The distributions in various phases of the cell cycle of U-251 MG cells treated with 0, TAU 24 mM, TMZ 500 µM, B2 and C2 for 24 h (a-e) and 48 h (f-j) are shown in the flow cytometric histograms, respectively. (k-n) represent the percentage of each phase as mean ± SEM. *p < 0.05, **p < 0.01, ****p < 0.0001 compared with control at same time. #p < 0.05, ##p < 0.01 compared with TMZ at same time. $p < 0.05, $$p < 0.01, $$$p < 0.0001 compared with TAU at same time.

Combinations in U-251 MG cells were also investigated. The expression levels of the apoptotic and anti-apoptotic markers were observed (Figure 5) after treatment with TAU, TMZ, B2, and C2 for 24h and 48h. An apoptotic marker, BAX (Figure 5a, c) in cells treated with B2 and C2 were significantly increased at 48h compared to a control group. In contrast, the expression of Bel-2, an anti-apoptotic marker at 48h was prone to decrease in C2 treatment (Figure 5a-b). Like Bel-2, AKT expression was also prone to decrease after treatment for 48h (Figure...
Synergistic Effects of Taurine and Temozolomide on Glioblastoma Cell

5a, d). However, the expressions of Bcl-2 and AKT were non-significantly decreased compared to a control group.

Discussion

GBM is one of tumors that is difficult to treat because of its high resistance to TMZ which is the standard regimen for GBM treatment (Bleeker et al., 2012). Thus, the combination of therapeutic agents is a path to enhance therapeutic efficacy in this tumor. However, no study applies the combination between TAU and TMZ in GBM therapy. Therefore, the aim of this study was to examine the antitumor effects of TMZ and TAU combination on GBM.

The inhibition of cell proliferation was indicated as cytotoxicity of the substances. Previous studies revealed that TAU inhibited cell proliferation in various cancer cells, for example, colon cancer cells (Zhang et al., 2014; Liu et al., 2018), breast cancer cells (Zhang et al., 2015), lung cancer cells (Tu et al., 2018), nasopharyngeal carcinoma cells (He et al., 2018), Ehrlich ascites carcinoma (Ibrahim et al., 2018). In the present study, we found that TAU also inhibited cell proliferation in U-251 MG cells in a dose-dependent manner. Despite, TMZ is a major drug in the treatment of GBM, but the resistant rate of TMZ has highly occurred. Therefore, TMZ in several studies had been applied to combine with other agents including resveratrol (Lin et al., 2012), chloroquine (Lee et al., 2015), curcumin (Zanotto-Filho et al., 2015), rutin (Zhang et al., 2017), and caffeine (Li et al., 2018) as new strategies in GBM treatment. The present results revealed that TMZ could not inhibit cell proliferation at a high concentration of 500 µM. This referred that U-251 MG might be resistant to TMZ. However, the combination between TMZ and TAU showed a synergistic effect on inhibition of tumor cell viability. By Chou-Talalay method to evaluate the interactions, ranges of CI including 0.85-0.90, 0.7-0.85, 0.7-0.3, 0.1-0.3, and <0.1 can represent the degree of synergism comprising of slight synergism, moderate synergism, synergism, strong synergism, and very strong synergism, respectively (Chou and Martin, 2005). The combinations C2 (TAU (12mM) and TMZ (375µM) ratio TAU:TMZ = 32:1) showed the strongest synergism (CI=0.69177) among others at 48 h after treatment. Moreover, results showed that C2 significantly decreased cell viability when compared to control or TMZ (500µM) alone and cytotoxicity of C2 was comparable with TAU (24mM) alone. According to the results, the dosages of combined agents were reduced as well as provided cytotoxicity effect on U-251 MG cells similar to single-agent with the higher dose. Therefore, the dose reduction with equivalent therapeutic effect might be a way to improve the strategy of treatment by adverse drug reaction reduction of chemotherapeutic drugs.

In the present study, it was revealed that the combination between TMZ and TAU induced U-251 MG cell apoptosis by the increase of nuclear chromatin condensation, DNA fragmentation, and Annexin V and PI-positive cells. Apoptosis is well known as programmed cell death. Basically, the molecules in cells involving apoptotic balance include Bcl-2, an anti-apoptotic protein, and Bax proteins, pro-apoptotic protein (Adams and Cory, 2007). Apart from Bcl-2 and Bax, Akt also regulates apoptosis at a postmitochondrial level by inhibiting activation of caspase-9 and -3 which are the effector molecules for the apoptotic process (Zhou et al., 2000). The present study found that C2 has a synergistic effect to significantly induce apoptosis in U-251 MG cells at 48 h after treatment.
However, we also found that Bcl-2 and Akt proteins were non-significantly down-regulated in U-251 MG cells. In contrast, Bax protein was significantly upregulated after treatment with B2 and C2 for 48 h. Thus, the results suggested that apoptosis by the combination of TMZ and TAU might not relate with downregulation of Bcl-2 and Akt proteins in U-251 MG cells. Apart from Bcl-2, previous studies reported that PUMA (p53-upregulated modulator of apoptosis), a member of the BH3-only subgroup of Bcl-2 family proteins and a potent pro-apoptotic protein was upregulated after treatment with TAU in colorectal cancer cells (Zhang et al., 2014), breast cancer cell (Zhang et al., 2015), and lung cancer A549 cell (Tu et al., 2018) to induce apoptosis. Thus, PUMA should be further investigated for other mechanisms of apoptosis.

A characteristic of cancer cells is the high proliferative rate associated with some mutations, especially at regulatory genes of the cell cycle resulting in cell avoiding from the checkpoint mechanisms and then occurring the unlimited proliferation of cancer cells (DiPaola et al., 2002). In the present study using flow cytometry, we found that a G2/M arrest in the cell cycle was induced after treatment with TMZ, B2, or C2 for 24 h. Then, contents of DNA fragments were significantly increased in the subG1 phase after treatment with TMZ, B2, or C2 for 48 h. These results suggested that G2/M arrest might induce apoptotic cells indicated by DNA fragment content in the subG1 phase after treatment with C2 for 48 h. Increasing apoptotic cells after treatment with C2 for 48 h in cell cycle investigation had the same trend as Annexin V and PI-positive cells. In other studies, they have previously been reported that the treatment of GBM cells with TMZ or agents combined with TMZ induced cell cycle arrest at G2/M phase (Li et al., 2018; Lee et al., 2015) and increased apoptotic cells in a time-dependent manner (Zhang et al., 2012; Zanotto-Filho et al., 2015).

In conclusion, all results presented in this study reveal that the combination between TMZ and TAU provides a synergistic effect to enhance cytotoxicity on U-251 MG cells in term of cell proliferation inhibition and apoptosis induction. These results provide a novel strategy for improving the antitumor activity of TMZ and TAU against GBM in the future.

Author Contribution Statement

Study conception and design: Thanakorn Surarak. Data collection: Thanakorn Surarak. Analysis and interpretation of the results: Thanakorn Surarak. Draft Manuscript Preparation: Thanakorn Surarak, Pathanin Chantree, and Kant Sangpairoj. All authors reviewed the results and approved the final version of the manuscript.

Acknowledgements

Funding statement

This study was supported by a research fund from the Faculty of Medicine, Thammasat University, Thailand (Contract No. 2-09/2562) to Thanakorn Surarak and a research grant of Thammasat University Research Unit in Nutraceuticals and Food Safety, Faculty of Medicine, Thammasat University, Pathumthani, Thailand.

Data Availability

All relevant data are within the paper.

Declaration of Conflicts of Interest

The authors declare no conflict of interest.

References

Adams JM, Cory S (2007). Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol, 19, 488-96.
Bleeker FE, Molenar RJ, Leenstra S (2012). Recent advances in the molecular understanding of glioblastoma. J Neurooncol, 108, 11-27.
Chou TC (2010). Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res, 70, 440-6.
Chou TC, Martin N (2005). Scope of applications. In ‘Compusyn for drug combination and for general dose-effect analysis: user’s guide’, Eds 34.
Curran PP, Marczinski CA (2017). Taurine, caffeine, and energy drinks: Reviewing the risks to the adolescent brain. Birth Defects Res, 109, 1640-8.
DiPaola RS (2002). To arrest or not to G(2)-M Cell-cycle arrest : commentary re: A. K. Tyagi et al., Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G(2)-M arrest, and apoptosis. Clin Cancer Res, 8, 3512-9, 2002.
Gao P, Yang C, Nesvick CL, et al (2016). Hypotaurine evokes a novel phenotype in glioma through aberrant hypoxic signaling. Oncotarget, 7, 15200-14.
Goron A, Moinard C (2018). Amino acids and sport: a true love story?. Amino Acids, 50, 969-80.
He F, Ma N, Midorikawa K, et al (2018). Taurine exhibits an apoptosis-inducing effect on human nasopharyngeal carcinoma cells through PTEN/Akt pathways in vitro. Amino Acids, 50, 1749-58.
Ibrahim HM, Abdel Ghaffar FR, El-Elaimy IA, et al (2018). Antitumor and immune-mediator efficacy of dual-treatment based on levamisole and/or taurine in Ehrlich ascites carcinoma-bearing mice. Biomed Pharmacother, 106, 43-9.
Lee SW, Kim HK, Lee NH, et al (2015). The synergistic effect of combination temozolomide and chloroquine treatment is dependent on autophagy formation and p53 status in glioma cells. Cancer Lett, 360, 195-204.
Lee SY (2016). Temozolomide resistance in glioblastoma multiforme. Genes Dis, 3, 198-210.
Li N, Zhang P, Kiang KMY, et al (2018). Caffeine sensitizes U87-MG human glioblastoma cells to temozolomide through mitotic catastrophe by impeding G2 arrest. Biomed Res Int, 2018, 5364973.
Lin CJ, Lee CC, Shih YL, et al (2012). Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radic Biol Med, 52, 377-91.
Liu Z, Xia Y, Zhang X, et al (2018). Roles of the MST1-JNK signaling pathway in apoptosis of colorectal cancer cells induced by Taurine. Libyan J Med, 13, 1500346.
Miranda-Filho A, Pineros M, Soerjomataram I, et al (2017). Cancers of the brain and CNS: global patterns and trends in incidence. Neuro Oncol, 19, 270-80.
Schaffer S, Kim HW (2018). Effects and mechanisms of taurine as a therapeutic agent. Biomol Ther (Seoul), 26, 225-41.
Synergistic Effects of Taurine and Temozolomide on Glioblastoma Cell

Seidel U, Huebbe P, Rimbach G (2019). Taurine: A regulator of cellular redox homeostasis and skeletal muscle function. *Mol Nutr Food Res*, 63, e1800569.

Shergalis A, Bankhead A, 3rd, Luesakul U, et al (2018). Current challenges and opportunities in treating glioblastoma. *Pharmacol Rev*, 70, 412-45.

Tu S, Zhang XL, Wan HF, et al (2018). Effect of taurine on cell proliferation and apoptosis human lung cancer A549 cells. *Oncol Lett*, 15, 5473-80.

Urbanska K, Sokolowska I, Szmidt M, et al (2014). Glioblastoma multiforme - an overview. *Contemp Oncol (Pozn)*, 18, 307-12.

Witthayanuwat S, Pesec M, Supaadirek C, et al (2018). Survival analysis of glioblastoma multiforme. *Asian Pac J Cancer Prev*, 19, 2613-7.

Zanotto-Filho A, Braganhol E, Klaflke K, et al (2015). Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas. *Cancer Lett*, 358, 220-31.

Zhang J, Stevens MF, Bradshaw TD (2012). Temozolomide: mechanisms of action, repair and resistance. *Curr Mol Pharmacol*, 5, 102-14.

Zhang P, Sun S, Li N, et al (2017). Rutin increases the cytotoxicity of temozolomide in glioblastoma via autophagy inhibition. *J Neurooncol*, 132, 393-400.

Zhang X, Lu H, Wang Y, et al (2015). Taurine induces the apoptosis of breast cancer cells by regulating apoptosis-related proteins of mitochondria. *Int J Mol Med*, 35, 219-26.

Zhang X, Tu S, Wang Y, et al (2014). Mechanism of taurine-induced apoptosis in human colon cancer cells. *Acta Biochim Biophys Sin (Shanghai)*, 46, 261-72.

Zhou H, Li XM, Meinkoth J, et al (2000). Akt regulates cell survival and apoptosis at a postmitochondrial level. *J Cell Biol*, 151, 483-94.

This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.